Pulmonary Embolism – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pulmonary Embolism – Drugs In Development, 2024 report and make more profitable business decisions.
Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat, and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.
The Pulmonary Embolism drugs in development market research report provide comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pulmonary Embolism | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 16 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pulmonary Embolism therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pulmonary Embolism pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pulmonary Embolism treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acticor Biotech SASAnthos Therapeutics Inc
Bayer AG
Bio-Synectics Inc
CarboMimetics
China Resources Emde Biological Pharmaceutical Co Ltd
Guangzhou Recomgen Biotech Co Ltd
Indiana Lysis Technologies LLC
Kolmar Korea Co Ltd
Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd
SupraGen LLC
Taho Pharmaceuticals Ltd
Techfields Pharma Co Ltd
Translational Sciences Inc
Verseon Corp
Zonhon Biopharma Institute Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pulmonary Embolism reports